LTIMINDTREE/AFORZA
4.4.2024 12:53:31 CEST | Business Wire | Press release
Aforza, the leading cloud and mobile solution specifically built for the Consumer Products industry that empowers businesses of all sizes to protect margins on every channel, and LTIMindtree (NSE: LTIM, BSE: 540005), a global technology consulting and digital solutions company, today announced a strategic partnership to deliver digital transformation in CRM & TPM across the consumer products industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404866939/en/
The partnership between Aforza and LTIMindtree is set to support the front office operations of Consumer Products manufacturers and distributors. This collaboration aims to empower businesses to grow profitably and safeguard margins through comprehensive omnichannel pricing control. It will enable access to real-time data insights, enhancing planning and decision-making capabilities. Additionally, the partnership promises to boost field productivity throughout the value chain by delivering a world-class user experience. With industry-specific offline mobile apps, professionals can work from anywhere, ensuring flexibility and efficiency. The initiative will also focus on increasing distribution, availability, stock accuracy, and fulfilment rates. Furthermore, it will provide robust measures to manage compliance issues effectively and prevent fraud, ensuring a secure and compliant operational environment.
Nachiket Deshpande, Whole-Time Director & Chief Operating Officer, LTIMindtree said, “We strongly believe in investing in our talent to stay ahead of the curve and to help our customers in the Consumer Goods space. With Aforza’s AI innovations and their digital content execution capabilities, the training for our consultants will add to their domain skills and elevate their advisory and implementation capabilities. We see this partnership grow and create an ecosystem of well trained and skilled individuals who will bring exceptional results to our customer.”
“This strategic partnership marks a pivotal moment in our commitment to empowering Consumer Product companies with cutting-edge digital solutions,” says Ed Butterworth, Chief Commercial Officer & Co-Founder of Aforza. “By combining Aforza's industry-specific expertise and LTIMindtree's digital transformation leadership, we will deliver unparalleled value to our customers, fostering growth, innovation, and sustainable success.”
LTIMindtree has established the Aforza Training Academy, with Aforza’s Customer Success Enablement team, to virtually train and certify a full practice of industry consultants. This is a key enabler to build customer success and trust. Collectively, Aforza and LTIMindtree will focus on key segments within the Consumer Products industry, including Beauty, Consumer Healthcare, Luxury Brands, and Food & Beverage.
About Aforza
Aforza helps Consumer Product companies grow confidently & protect margins in uncertain times through a suite of cloud & mobile apps built for the industry. Aforza connects trade planning and field sales teams together to solve the problems of margin erosion, missed revenue opportunities and ineffective trade spend. The Aforza product works out of the box and can be implemented in weeks. The mobile applications work offline and deliver powerful on-device intelligence across Apple iOS and Android devices. Aforza is built on the Salesforce and Google Cloud Platforms which means we can scale fast and deliver continuous innovation with 3 releases a year. Customer success is Aforza's top priority, and we are proud to be trusted by CPG companies in more than 40 countries; including leading breweries, food & beverage manufacturers, consumer healthcare companies and major distributors. To learn more, please visit www.aforza.com
About LTIMindtree
LTIMindtree is a global technology consulting and digital solutions company that enables enterprises across industries to reimagine business models, accelerate innovation, and maximize growth by harnessing digital technologies. As a digital transformation partner to more than 700 clients, LTIMindtree brings extensive domain and technology expertise to help drive superior competitive differentiation, customer experiences, and business outcomes in a converging world. Powered by 82,000+ talented and entrepreneurial professionals across more than 30 countries, LTIMindtree — a Larsen & Toubro Group company — combines the industry-acclaimed strengths of erstwhile Larsen and Toubro Infotech and Mindtree in solving the most complex business challenges and delivering transformation at scale. For more information, please visit https://www.ltimindtree.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404866939/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom